The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Second cancers following pediatric Hodgkin's disease.
Abstract
PURPOSE: To define the magnitude of second cancer risk among pediatric Hodgkin's disease survivors and to determine which factors influence this risk. PATIENTS AND METHODS: At Stanford,694 children and teenagers were monitored for 1 to 31.6 years (mean, 13.1) after treatment for Hodgkin's disease. Relative risks (RRs), actuarial risks, and absolute excess risks for second malignancies were calculated. The influences of sex, age, stage, splenectomy, treatment and relapse were assessed by multivariate analysis. RESULTS: Fifty-six patients developed 59 secondary malignancies: 48 solid tumors, eight leukemias, and three non-Hodgkin's lymphomas. The RR of developing a second cancer was 15.4 (95% confidence interval [CI], 10.6 to 21.5) for females and 10.6 (95% CI, 6.6 to 16.0) for males. Breast cancer (n = 16) and sarcoma (n = 13) were the most common solid tumors. The actuarial risk at 20 years follow-up evaluation was 9.7% for males, 16.8% for females, and 9.2% for breast cancer. The median interval to diagnosis of a second malignancy was shortest for leukemia, 4.3 years, and longest for lung cancer, 18.4 years. Relapse of Hodgkin's disease increased the risk of second malignancy (hazards ratio [HR] = 2.6, P < .001). Hodgkin's disease stage, patient age, splenectomy, and treatment modality did not appear to alter overall risk, although chemotherapy was associated with subsequent leukemia. CONCLUSION: Aggressive Hodgkin's disease therapy is successful, but patients have a significant risk of second malignancy. Newer treatment programs focus on obtaining a relapse-free cure of Hodgkin's disease with judicious use of radiation and alkylating agent chemotherapy. Survivors of pediatric Hodgkin's disease require lifelong evaluation and cancer screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F., & Meadows, A. T. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341201 · Cited by 905
Huerta, G. T., & Villasana, J. E. M. (1988) · PubMed · Cited by 804
Bone Sarcomas Linked to Radiotherapy and Chemotherapy in Children
Tucker, M. A., D'Angio, G. J., Boice, J. D., Strong, L. C., Li, F. P., Stovall, M., Stone, B. J., Green, D. M., Lombardi, F., Newton, W., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171002 · Cited by 765
Risk of Second Cancers after Treatment for Hodgkin's Disease
Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A., & Rosenberg, S. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180203 · Cited by 718
Breast Cancer After Treatment of Hodgkin's Disease
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.25 · Cited by 536
Leukemia Following Hodgkin's Disease
Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220102 · Cited by 485
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., van Heerde, P., & Somers, R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.312 · Cited by 443
Cited by
Neglia, J. P., Friedman, D. L., Yasui, Y., Mertens, A. C., Hammond, S., Stovall, M., Donaldson, S. S., Meadows, A. T., & Robison, L. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.618 · Cited by 741
Self-citationIn search of the tumour-suppressor functions of BRCA1 and BRCA2
Scully, R., & Livingston, D. M. (2000) · Nature · doi:10.1038/35044000 · Cited by 643
Bhatia, S., Yasui, Y., Robison, L. L., Birch, J. M., Bogue, M. K., Diller, L., DeLaat, C., Fossati-Bellani, F., Morgan, E., Oberlin, O., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.059 · Cited by 613
Dores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., van Leeuwen, F. E., Holowaty, E. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.038 · Cited by 565
van Leeuwen, F. E., Klokman, W. J., Veer, M. B. V., Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.487 · Cited by 436
Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings
Diller, L., Chow, E. J., Gurney, J. G., Hudson, M. M., Kadan-Lottick, N. S., Kawashima, T. I., Leisenring, W. M., Meacham, L. R., Mertens, A. C., Mulrooney, D. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1953 · Cited by 415
van Leeuwen, F. E., Klokman, W. J., Stovall, M., Dahler, E. C., van't Veer, M. B., Noordijk, E. M., Crommelin, M. A., Aleman, B. M. P., Broeks, A., Gospodarowicz, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.971 · Cited by 402
Genetic and Hormonal Risk Factors in Breast Cancer
Martin, A.-M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1126 · Cited by 371
Sklar, C., Whitton, J., Mertens, A., Stovall, M., Green, D., Marina, N., Greffe, B., Wolden, S., & Robison, L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6808 · Cited by 355
Self-citationSecond Cancers Among Long-Term Survivors of Hodgkin’s Disease Diagnosed in Childhood and Adolescence
Metayer, C., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., Joensuu, T., van Leeuwen, F. E., van’t Veer, M. B., Curtis, R. E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2435 · Cited by 340
New Malignant Diseases After Allogeneic Marrow Transplantation for Childhood Acute Leukemia
Socié, G., Curtis, R. E., Deeg, H. J., Sobocinski, K. A., Filipovich, A. H., Travis, L. B., Sullivan, K. M., Rowlings, P. A., Kingma, D. W., Banks, P. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.348 · Cited by 337
Association of CYP 3 A 4 genotype with treatment-related leukemia
Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N.-K. V., Lovett, B. D., Nowell, P. C., Blair, I. A., & Rebbeck, T. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13176 · Cited by 310
Tubiana, M. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.12.016 · Cited by 280
Second cancers in survivors of childhood cancer
Bhatia, S., & Sklar, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc722 · Cited by 268
Allan, J. M., Wild, C. P., Rollinson, S., Willett, E. V., Moorman, A. V., Dovey, G. J., Roddam, P. L., Roman, E., Cartwright, R. A., & Morgan, G. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191211198 · Cited by 268
Appel, B. E., Chen, L., Buxton, A. B., Hutchison, R. E., Hodgson, D. C., Ehrlich, P. F., Constine, L. S., & Schwartz, C. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.3469 · Cited by 77
Metadata
- Authors
- Wolden, S. L., Lamborn, K. R., Cleary, S. F., Tate, D. J., & Donaldson, S. S.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-02
- Volume
- 16
- Issue
- 2
- Pages
- 536-544
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2223071669
- Cited by
- 268
- References
- 28
- FWCI
- 19.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.